医药生物行业周报（4月第1周）：医疗器械板块利好政策频出-2025-04-07

Investment Rating - The report does not explicitly state an investment rating for the medical device sector, but it highlights positive developments and opportunities within the industry. Core Insights - The medical and biological sector saw a weekly increase of 1.2%, outperforming the Wind All A index (-1.17%) and the CSI 300 index (-1.37%) during the week of March 31 to April 3, 2025 [2][7]. - High-end medical devices are expected to benefit from favorable policies, including a draft proposal from the National Medical Products Administration aimed at optimizing lifecycle regulation and supporting innovation in high-end medical devices such as surgical robots and AI medical devices [2][12]. - The acceleration of centralized procurement for large medical equipment is likely to enhance the market share of domestic medical device companies, as multiple regions, including Guangxi, have initiated procurement processes for 2025 [2][12]. Market Weekly Review - The medical and biological sector rose by 1.2%, with offline pharmacies (4.15%), chemical preparations (3.92%), and medical consumables (1.66%) leading the gains, while medical research outsourcing (-3.19%), medical devices (-1.48%), and hospitals (-0.15%) faced declines [2][7]. - The top three gaining stocks were Duorui Pharmaceutical (56.3%), Weisi Medical (31.8%), and Hasanlian (31.3%), while the top three decliners were Dongfang Biology (-11.1%), Dongfang Ocean (-9.2%), and Nengte Technology (-9.1%) [2][10]. Industry News and Key Company Announcements - The National Medical Products Administration is seeking opinions on measures to support the innovation of high-end medical devices, which includes ten key initiatives aimed at enhancing the regulatory framework [2][12]. - Guangxi Public Resources Trading Center announced the initiation of centralized procurement for large medical devices for 2025, encouraging both government and non-government entities to participate [2][12]. - Amgen announced FDA approval for a new indication of its CD19 antibody Inebilizumab, marking a significant development in the treatment of IgG4-related disease [2][12]. - Pfizer registered a Phase III clinical trial for its recombinant RSV vaccine in China, aiming to compare immunogenicity and safety between Chinese and American populations [2][12].